⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AUTL News
Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
globenewswire.com
AUTL
Engineered T Cells Market - Global Forecast 2026-2032 | CAR-T, TCR-T, and Allogeneic Platforms Unlock 8.06% CAGR and a USD 41.99 Billion Opportunity
globenewswire.com
ALLO
AMGN
ATRA
AUTL
BB
BMY
CRSP
FATE
GILD
IMCR
REGN
PFE
SANG
TCRT
Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development
globenewswire.com
BNTX
AUTL
T-Cell Malignancies (CTCL and PTCL) - 7MM Market Insights, Epidemiology, and Forecast - 2036 | Market to Reach USD 3.17 Billion as Targeted Therapies Advance
globenewswire.com
BIIB
PFE
TSEM
CRVS
AUTL
SLGN
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
globenewswire.com
AUTL
Europe CAR-T Therapies Market for Autoimmune Disorders: Trends, Growth, and Forecast to 2035 | 47.4% CAGR Signals a USD 1.25 Billion Opportunity as Clinical Pipelines Advance
globenewswire.com
AUTL
KYMR
NVS
SANA
JNJ
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
globenewswire.com
GILD
NVS
BMY
CRSP
BIO
ADBT
BIIB
JNJ
REGN
AMGN
CELC
ALLO
MBIO
AUTL
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight
globenewswire.com
NVS
ALLO
LEGN
CBIO
MBIO
CRSP
INCY
IMPP
SANA
VOR
CARG
AUTL
ARCL
LYEL
PRE
BEAM
CART
TAK
AZN
MRK
BMY
GEN
DGX
GMAB
ABBV
RLGT
CRGO
JNJ
GILD
JAZZ
SYBX
CASI
ATRA
SHEN
BIIB
VREX
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
globenewswire.com
AUTL
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
prnewswire.com
CLLS
AUTL
FATE
GILD
NVS